AI Life Sciences Workflow

Foundation biology models are becoming investable infrastructure bets

The sector is witnessing a structural shift from point-solution AI tools to full-stack biology foundation models commanding outsized capital and elite investor conviction. Chai Discovery — an AI-native foundation model lab for molecule engineering — attracted co-founders from OpenAI, Stripe, Pfizer, and Genentech, and landed Sequoia, Kleiner Perkins, Index Ventures, Thrive, and Baillie Gifford in a $400M Series B at a $3.8B valuation. Cellular Intelligence secured Yann LeCun and Moderna co-founder Robert Langer on its Scientific Advisory Board, signaling that the most credentialed AI and biotech minds are converging on predictive cell-behavior models. Astromech's narrowly focused evolutionary genomic AI — covering cancer drug design, bird flu prediction, and therapeutic development — illustrates that domain-specific biology models don't need frontier compute to carve defensible positions, a structural cost advantage the market is beginning to price in.

Enterprise life sciences organizations are paying premium prices for AI that operates inside regulated workflows, not adjacent to them. The $2B acquisition of ArisGlobal by Dassault Systèmes and Siemens' $5.1B acquisition of Dotmatics both demonstrate strategic buyers are willing to pay top dollar for regulatory and R&D workflow software moats. Thermo Fisher Scientific — a flagship OpenAI enterprise customer — is actively using AI to accelerate FDA drug approvals, validating that the largest pharma incumbents are integrating AI into their most regulated processes. Benchling's AI-powered life sciences platform continues to attract aggressive recruiting, reflecting sustained enterprise demand for scientific knowledge-work automation.

Why it matters · Companies that embed deeply into FDA-adjacent workflows gain switching costs that make them near-impossible to displace, justifying the premium multiples strategic acquirers are paying.

Basecamp Research's round — backed by NATO Innovation Fund and Nvidia alongside traditional VCs — signals a new capital archetype entering AI biotech: defense and sovereign funds treating biological AI as strategic national infrastructure. This convergence of defense, sovereign AI, and biotech capital pools represents a potential template for dual-use startups building on biodiversity and genomic data assets.

Why it matters · Founders who can credibly frame their biological AI platforms as sovereign or dual-use assets unlock a non-dilutive and strategically patient capital pool that traditional biotech VCs cannot match.

A new product archetype is emerging that sits between AI protein design and physical experimental validation: Infera's AI-native lab compiler lets researchers describe experiments in plain English and translates them into validated, instrument-ready runs on existing equipment. Adaptyv Biosystems raised a Series A positioning itself as the factory floor of this loop, with standardized high-frequency assay data as its core moat. The insight is that defensibility in AI-adjacent lab hardware accumulates in the software and data flywheel, not the hardware itself.

Why it matters · Platforms that own the standardized data layer between AI design and physical lab execution will become the de facto operating system for next-generation drug discovery pipelines.

Open Evidence — an AI platform for clinical evidence and medical information — is now being used by physicians in practice to query medical knowledge, and was cited by Sarah Guo alongside Harvey and Sierra as proof that vertical AI players can succeed even in markets theoretically on a frontier lab's roadmap. Ethermed is automating up to 90% of prior authorizations with a 91% first-pass approval rate by integrating directly with EHR systems, turning a pure administrative burden into a measurable revenue outcome for health systems.

Why it matters · Clinical AI solutions with proven workflow integration and measurable outcome metrics are crossing the threshold from pilot to enterprise contract, creating durable ARR that justifies growth-stage valuations.